Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes
Autor: | Kim M. Gooding, Myo Myo Aung, Kate Slade, Leighton A. R. Freeman, Katarina Kos, Jacqueline L. Whatmore, Angela C. Shore |
---|---|
Rok vydání: | 2019 |
Předmět: |
Glucagon-like peptide-1 analogues
Adult Male 0301 basic medicine Microvascular perfusion Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism Type 2 diabetes Pharmacology Article 03 medical and health sciences 0302 clinical medicine Glucagon-Like Peptide 1 Enos Diabetes mellitus Internal Medicine medicine Humans Obesity Saline Aged Macrovascular disease Aged 80 and over biology business.industry Liraglutide Microcirculation Hemodynamics Middle Aged medicine.disease biology.organism_classification 030104 developmental biology Diabetes Mellitus Type 2 Linear Models Exenatide Female business Perfusion medicine.drug |
Zdroj: | Diabetologia |
ISSN: | 1432-0428 0012-186X |
DOI: | 10.1007/s00125-019-4918-x |
Popis: | Aims/hypothesis Glucagon-like peptide-1 (GLP-1) analogues reduce the risk of macrovascular disease in diabetes; however, little is known about their microvascular effects. This research examined the microvascular actions of the GLP-1 analogues liraglutide and exenatide in individuals with and without type 2 diabetes (study 1). It also explored the involvement of the GLP-1 receptor (study 2) and the nitric oxide pathway in mediating the microvascular effects of the analogues. Methods Trial design: Studies 1 and 2 had a randomised, controlled, double-blind study design. Study 1 participants, intervention and methods: three participant groups were recruited: individuals with well-controlled type 2 diabetes, and obese and lean individuals without diabetes (21 participants per group). Liraglutide (0.06 mg), exenatide (0.5 μg) and saline (154 mmol/l NaCl; 0.9%) control were microinjected into separate sites in the dermis (forearm) in a randomised order, blinded to operator and participant. Skin microvascular perfusion was assessed by laser Doppler perfusion imaging. Outcomes were stabilised response (mean skin perfusion between 7.5 and 10 min post microinjection) and total response (AUC, normalised for baseline perfusion). Perfusion response to GLP-1 analogues was compared with saline within each group as well as between groups. Study 2 participants, intervention and methods: in healthy individuals (N = 16), liraglutide (0.06 mg) and saline microinjected sites were pretreated with saline or the GLP-1 receptor blocker, exendin-(9,39), in a randomised order, blinded to participant and operator. Outcomes were as above (stabilised response and total perfusion response). Perfusion response to liraglutide was compared between the saline and the exendin-(9,39) pretreated sites. In vitro study: the effects of liraglutide and exenatide on nitrate levels and endothelial nitric oxide synthase phosphorylation (activation) were examined using human microvascular endothelial cells. Results Study 1 results: both analogues increased skin perfusion (stabilised response and total response) in all groups (n = 21 per group, p |
Databáze: | OpenAIRE |
Externí odkaz: |